Congressionally Directed Medical Research Programs -- Pancreatic Cancer Research Program -- Translational Research Partnership Award

Funding Agency:
Department of Defense

The FY20 PCARP Translational Research Partnership Award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in pancreatic cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must function as a research scientist and the other partner as a clinician investigator. It should be clear that both have had equal intellectual input in the design of the research project. Multi-institutional and multi-discipline partnerships are strongly encouraged. At least one partner must have expertise either in pancreatic cancer research or pancreatic cancer patient care. Inclusion of experts from outside the pancreatic cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism. Full support for large scale clinical trials is not expected; retrospective tissue analysis, correlative studies, or small pilot clinical trials are permitted.


  • Required Pre-Application Submission Deadline: August 25, 2020
  • Invitation to Submit an Application: September 30, 2020
  • Application Submission Deadline: November 20, 2020

Agency Website

Areas of Interest

To be considered for funding, applications for the FY20 PCARP Translational Research Partnership Award must address at least one of the FY20 PCARP Focus Areas.

  • Understanding precursors, origins, and early progression of pancreatic cancer
  • Understanding the events that promote pancreatic cancer metastasis
  • Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response
  • Integration of biologic and imaging biomarkers to drive more precise and earlier detection and prognosis
  • Defining viable tumor burden
  • Supportive care and patient-reported outcomes, quality of life, and perspectives during treatment and survivorship
  • New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance
  • Development of pharmacological, immunological, or genetic interception approaches

Eligibility Requirements

PIs must be at or above the level of Assistant Professor or equivalent. Clinician investigators must be an M.D., M.D./Ph.D., or equivalent with clinical duties and/or responsibilities. Postdoctoral and clinical fellows are not eligible. One partner in the collaboration must function as a research scientist and the other as a clinician investigator.



Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY20 PCARP Translational Research Partnership award will not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type



Junior Faculty


Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

August 25, 2020